छोड़कर सामग्री पर जाएँ

Concord Biotech hits 52-week high after Jefferies initiates #39;buy#39; call; sees 19% upside

  • द्वारा
  • Latest News

Jefferies also prefers Concord Biotech over its peer Glenmark Life Sciences due to its superior growth profile, strong execution track record, industry-leading margins, and favourable return ratios.

Read More

​ Jefferies also prefers Concord Biotech over its peer Glenmark Life Sciences due to its superior growth profile, strong execution track record, industry-leading margins, and favourable return ratios. Jefferies also prefers Concord Biotech over its peer Glenmark Life Sciences due to its superior growth profile, strong execution track record, industry-leading margins, and favourable return ratios.  Moneycontrol Latest News Read More  

प्रातिक्रिया दे

आपका ईमेल पता प्रकाशित नहीं किया जाएगा. आवश्यक फ़ील्ड चिह्नित हैं *

hi_INहिन्दी